⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
SLXN News
Silexion Therapeutics Corp Ordinary Shares
Form 8-K
sec.gov
SLXNW
SLXN
Form 8-K
sec.gov
SLXNW
SLXN
Silexion Therapeutics Successfully Initiates Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer at Tel Aviv Sourasky Medical Center
globenewswire.com
SLXN
Form 8-K
sec.gov
SLXN
SLXNW
Silexion Therapeutics Receives Approval from Germany's BfArM to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer
globenewswire.com
SLXN
Silexion Therapeutics to Attend BIO International Convention 2026
globenewswire.com
SLXN
Form 8-K
sec.gov
SLXNW
SLXN
Form 8-K
sec.gov
SLXN
SLXNW
Silexion Therapeutics Announces 1-for-10 Reverse Share Split
globenewswire.com
SLXN
Form 8-K
sec.gov
SLXN
SLXNW